WELCHOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Welchol, and when can generic versions of Welchol launch?
Welchol is a drug marketed by Cosette and is included in four NDAs.
The generic ingredient in WELCHOL is colesevelam hydrochloride. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the colesevelam hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Welchol
A generic version of WELCHOL was approved as colesevelam hydrochloride by IMPAX LABS INC on May 16th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WELCHOL?
- What are the global sales for WELCHOL?
- What is Average Wholesale Price for WELCHOL?
Summary for WELCHOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Clinical Trials: | 28 |
| Patent Applications: | 1,161 |
| Drug Prices: | Drug price information for WELCHOL |
| What excipients (inactive ingredients) are in WELCHOL? | WELCHOL excipients list |
| DailyMed Link: | WELCHOL at DailyMed |
Recent Clinical Trials for WELCHOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Entera Health, Inc | Phase 2 |
| Valeant Pharmaceuticals International, Inc. | Phase 4 |
| Bausch Health Americas, Inc. | Phase 4 |
Pharmacology for WELCHOL
| Drug Class | Bile Acid Sequestrant |
| Mechanism of Action | Bile-acid Binding Activity |
Paragraph IV (Patent) Challenges for WELCHOL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| WELCHOL | Powder for Oral Suspension | colesevelam hydrochloride | 1.875 g/Packet and 3.75 g/Packet | 022362 | 1 | 2010-04-09 |
| WELCHOL | Tablets | colesevelam hydrochloride | 625 mg | 021176 | 1 | 2009-07-01 |
US Patents and Regulatory Information for WELCHOL
WELCHOL is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting WELCHOL
INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosette | WELCHOL | colesevelam hydrochloride | BAR, CHEWABLE;ORAL | 210895-001 | Apr 3, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-002 | Oct 2, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cosette | WELCHOL | colesevelam hydrochloride | CAPSULE;ORAL | 021141-001 | May 26, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-001 | Oct 2, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cosette | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for WELCHOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cosette | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-001 | Oct 2, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-001 | Oct 2, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-001 | Oct 2, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cosette | WELCHOL | colesevelam hydrochloride | BAR, CHEWABLE;ORAL | 210895-001 | Apr 3, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for WELCHOL
See the table below for patents covering WELCHOL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 698752 | ⤷ Sign Up | |
| Canada | 2191478 | PROCEDE POUR ELIMINER LES SELS BILIAIRES CHEZ UN PATIENT ET COMPOSITIONS ALKYLEES A CET EFFET (PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATEDCOMPOSITIONS THEREFOR) | ⤷ Sign Up |
| Austria | 184027 | ⤷ Sign Up | |
| European Patent Office | 0706399 | ⤷ Sign Up | |
| Brazil | 0209134 | ⤷ Sign Up | |
| Israel | 122383 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for WELCHOL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0764174 | SPC/GB04/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310 |
| 0764174 | 04C0021 | France | ⤷ Sign Up | PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/03/268/001 20040310 |
| 0764174 | 300159 | Netherlands | ⤷ Sign Up | 300159, 20150605, EXPIRES: 20190309 |
| 0764174 | CA 2004 00027 | Denmark | ⤷ Sign Up | |
| 0764174 | 91100 | Luxembourg | ⤷ Sign Up | 91100, EXPIRES: 20190310 |
| 0764174 | C300159 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
